Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9736359 | 0.73 | — | — | |
| SCHEMBL4727065 | 0.67 | NOTUM (0.30) | — | |
| SCHEMBL8610716 | 0.67 | MAPK1 (0.38) | — | |
| SCHEMBL5694237 | 0.57 | EP300 (0.34) | IKBKBMAP3K14 | |
| SCHEMBL28449256 | 0.56 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL5694084 | 0.55 | DNMT1 (0.37) | IKBKBMAP3K14 | |
| SCHEMBL3302482 | 0.55 | POLB (0.40) | — | |
| SCHEMBL31661211 | 0.50 | MAPK1 (0.40) | — | |
| Acetone SCHEMBL28276755 | 0.50 | LMNA (0.52) | IKBKBMAP3K14 | |
| Acetic Acid SCHEMBL9194364 | 0.48 | CYP1A2 (0.52) | IKBKBMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931693-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2008-06-18 | — | — | EP | claimed |
| WO-2007027564-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-03-08 | — | — | WO | claimed |
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016097989-A1 | PROCESS FOR THE PREPARATION OF GEMCITABINE HYDROCHLORIDE | KARIMIAN KHASHAYAR (IR) | 2016-06-23 | — | — | WO | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20080249119-A1 | Nucleosiding a protected cytosine with a protected hexose, deprotecting to obtain gemcitabine; administering as produgs; cancers of the lungs, ovaries, pancreas and bladder; cost efficiency; simplification | PHARMACON-FORSCHUNG UND BERATUNG GMBH (AT) | 2008-10-09 | — | — | US | disclosed |
| EP-1931693-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2008-06-18 | — | — | EP | disclosed |
| US-20070249823-A1 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-10-25 | — | — | US | disclosed |
| WO-2007070804-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007027564-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007015257-A2 | A PROCESS FOR THE PREPARATION OF GEMCITABINE USING NOVEL INTERMEDIATES | HETERO DRUGS LIMITED (IN) | 2007-02-08 | — | — | WO | disclosed |
| WO-2005095430-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF HIGH PURE GEMCITABINE HYDROCHLORIDE | POLTURI RAMESH BABU (IN) | 2005-10-13 | — | — | WO | disclosed |
| WO-2003059334-A2 | GEMCITABINE IN THE TREATMENT OF SMALLPOX | ELI LILLY AND COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| US-5118820-A | Carbohydrate is chemical intermediate for nucleoside | ELI LILLY AND COMPANY (US) | 1992-06-02 | — | — | US | disclosed |
| US-5015743-A | 2-Deoxy-2,2-difluororibose | ELI LILLY AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| US-4808614-A | Difluoro antivirals and intermediate therefor | ELI LILLY AND COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-4692434-A | NUCLEOSIDES | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249823-A1 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | DPYD, PARP1, PARP2 | IKBKB 2680/4885MAP3K14 2763/4885 |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | IKBKB 2697/4885MAP3K14 2606/4885 |
| US-20080249119-A1 | Nucleosiding a protected cytosine with a protected hexose, deprotecting to obtain gemcitabine; administering as produgs; cancers of the lungs, ovaries, pancreas and bladder; cost efficiency; simplification | TYMP, DUT, OGG1 | IKBKB 1461/4885MAP3K14 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.